News
Period app Flo Health reaches settlement in US data privacy lawsuit

The period tracking app has settled a US lawsuit over claims it shared users’ personal data with Meta without permission.
Flo Health says it has agreed to settle the class action lawsuit in which it was accused of sharing users’ health data with Meta for targeted advertising.
Founded in 2015, the Flo Health app now has over 75 million active users, becoming Europe’s first femtech unicorn after raising $230 million (£155.7m) in Series C investment in July 2024.
The app allows users to track period and ovulation cycles, monitor symptoms and access personalised health insights and educational content on topics such as pregnancy and perimenopause.
The case against Flo, which began on Monday, 21 July in San Francisco, involved five named claimants who said they did not permit personal data, including the dates and lengths of the periods, to be shared with the social media platform.
Flo Health denied all of the claims against it, while Meta denies receiving any sensitive data from the company.
No admission of wrongdoing
The company announced the settlement on Thursday, 31 July, after the judge presiding over the trial said the lack of evidence for the Plaintiff’s claim was an “insurmountable” problem.
“We are pleased to confirm that the matter has been resolved and that the facts came out at the trial,” a spokesperson for Flo Health said in a statement.
“We have always maintained that the claims lacked merit, and as the case progressed, the lack of evidence to support these allegations became increasingly clear in Court.”
They added: “Importantly, this settlement includes no admission of wrongdoing. We can now put the matter behind us so we can continue to focus on serving our customers and delivering our mission to advance the future of women’s health.”
Implications for the femtech sector
The high-profile case comes as some reports have raised questions around the governance of women’s health apps, suggesting users could be at risk of data breaches.
Stephanie Caird, life sciences partner at UK law firm Mills & Reeve, told Femtech World that calls for stricter regulations and “red tape” could affect user confidence in how their data is being used by femtech apps, leading to “nervousness”, with potential impacts for the wider sector.
Caird notes that jurisdictions such as the UK and the EU already have robust regulations in place regarding data compliance.
“There are already a variety of frameworks in place in the UK which, when taken together, should be providing a sufficiently robust framework to protect users’ data,” she says.
“From a data privacy perspective, the core takeaway from the case is that ‘privacy by design’ and ‘privacy by default’ are still very much core tenets of data privacy compliance, especially under EU and UK GDPR, which should be factored into the technology build stages.”
In 2023, the UK Information Commissioner’s Office (ICO) carried out a review of period and fertility apps, which did not identify any serious compliance issues or evidence of harm, in connection with the feedback received from app providers and app users.
“There was a reminder from the ICO to developers to ensure that data processing is undertaken in a compliant way,” Caird adds.
“That should continue to be a guiding principle for femtech companies collecting personal data.”
Flo says it ‘has never and will never’ sell users’ data, and its ‘commitment to user trust, data minimisation and security-by-design is rigorous, measurable and independently verified’.
It has recently introduced new privacy features such as Anonymous Mode, which it says demonstrates its ‘ongoing commitment to user trust’.
Menopause
Government and NHS urged to work with pharmacies on menopause support

The government and NHS England should work with pharmacies to show how the sector can help women experiencing menopause symptoms, according to a joint statement released by several pharmacy bodies.
A consensus statement endorsed by the Royal College of Pharmacy warned there remains significant unmet need for clear, evidence-based guidance and advice on the condition.
The statement, ‘Menopause, unmissed’, published on 24 April 2026, was endorsed by bodies including the Royal College of Pharmacy, the Company Chemists’ Association and the National Pharmacy Association.
Amandeep Doll, director for England at the Royal College of Pharmacy, said: “Pharmacy teams are highly accessible and already support people experiencing menopause with advice, self-care and signposting to other services.
“We endorsed this statement because improving access to clear information and joined-up care is essential, particularly for those facing inequalities.”
According to the NHS, around 75 per cent of women experience some symptoms during perimenopause and menopause, while 25 per cent report that their symptoms are severe.
In the joint statement, the pharmacy bodies welcomed increased awareness of menopause in recent years but warned this had also led to a sea of misinformation and that there remains significant unmet need, particularly for clear, evidence-based and accessible information and guidance.
The document set out eight recommendations to improve menopause care, including a public awareness campaign on menopause symptoms and opportunities for self-care, alongside guidance on how pharmacies can support women with menopause.
It also recommended that integrated care boards and women’s health hubs should report progress on implementing the upcoming equity framework in menopause care.
In its renewed women’s health strategy for England, published on 15 April 2026, the Department of Health and Social Care set out plans to publish an equity good practice guide to help integrated care boards better understand and reduce inequalities in heavy periods and menopause.
The joint statement asked that the Department of Health and Social Care and NHS England work with champions in minority communities to ensure menopause materials reflect a diverse range of experiences.
It added that women living in areas of high deprivation and those from Black, Asian and minority ethnic communities can experience menopause differently and are more likely to face health inequalities in their care.
Doll said: “With the right support, training and commissioning, community pharmacy can play a greater role in delivering timely, convenient menopause care closer to home, working as part of neighbourhood health teams and in partnership with women’s health hubs.”
Insight
Why the UK’s fertility rate keeps falling – and what it means if you’re trying now

Article produced in association with Spital Clinic
The UK’s fertility rate has fallen for a third consecutive year to the lowest level ever recorded. That headline gets written every year, and it is easy to read it as a purely demographic story.
For anyone currently trying for a baby, the figure is something more practical: the conditions that produced the statistic are the same conditions shaping your own chances.
The decline has a clear pattern, and it is mostly not about couples being unable to conceive.
The change sits in when people start trying, and in what happens to fertility during the years by which most are now ready to have children.
What the numbers actually show
Figures from the ONS put the total fertility rate in England and Wales at 1.41 children per woman in 2024, down from 1.42 in 2023. The rate has been in overall decline since 2010 and has now recorded its lowest value three years running.
The figure sounds abstract until you compare it with the replacement level of 2.1 – the rate required for a population to sustain itself without net migration.
The UK has been below that line since the early 1970s, but the gap is now wider than at any point on record.
The data also shows where the decline is happening. Age-specific fertility rates for women in their twenties are the lowest of any generation since 1920. Rates for women in their thirties are holding up, and in some parts of the country rising.
Mothers are having babies later, not necessarily in smaller numbers. The average age of a first-time mother in England and Wales is now 31.0, up from 30.9 the year before. Regional variation matters too: London sits at 1.35, the West Midlands at 1.59.
Why the rate is falling
None of this is new. Every decade since the 1970s has seen the same trend, and it has accelerated in recent years. What has changed is the pace.
The shift is primarily social: delayed partnership formation, high housing costs, expensive childcare, and careers structured around full-time work through the exact years fertility is easiest.
The same pattern shows up across the EU, where the total fertility rate sat at 1.5 in 2022.
These forces compound. People meet later, partner later, feel financially ready later, and start trying later.
For many couples, first attempts happen in the early thirties, by which point fertility has begun its slow and uneven decline. A low national TFR is the population-level consequence of millions of individual timing decisions made under real-world constraints.
What this means for individuals trying now
Around one in seven couples in the UK will struggle to conceive naturally.
That figure has been stable for decades; the population of people seeking help, however, has grown – not because fertility itself has worsened, but because more people are trying during the window where it becomes harder.
UK fertility treatment data from the HFEA shows around 52,400 patients had over 77,500 IVF cycles in 2023, making 1 in every 32 UK births IVF-conceived.
The average age of a first-time IVF patient in the UK is now just over 35 – nearly six years older than the average first-time mother in the population overall.
NHS-funded IVF cycles have fallen from 40 per cent of the total in 2012 to 27 per cent in 2022, and to 24 per cent in England in 2023. The private sector has absorbed the rest.
When to get checked – and what it involves
Current NHS advice is to see a GP after a year of regular unprotected sex without a pregnancy, or sooner if you are 36 or older.
That threshold reflects the fact that every additional six months of trying is more clinically informative in the years when fertility is starting to shift.
The first set of investigations is usually straightforward.
For women, this typically covers hormone testing (AMH, FSH, LH, TSH and prolactin), rubella immunity, chlamydia screening, a mid-luteal progesterone and a transvaginal ultrasound.
For men, a semen analysis is the first step.
A private trying-to-conceive screening covers the same ground without the NHS waiting list, with the advantage that results can be reviewed in a single consultation.
The purpose of early screening is not to diagnose infertility – most couples conceive naturally within a year or two – but to identify specific, treatable issues before more time passes.
The fertility window is narrower than most people think
The uncomfortable truth behind the falling TFR is that the biological fertility window has not changed. The subtle decline begins around age 32, and accelerates from the late thirties.
The chance of natural conception in any given month is substantially lower at 40 than at 30, and falls sharply through the early forties.
IVF success rates track the same curve.
For patients aged 18 to 34, the average birth rate per embryo transferred was around 35 per cent in 2022; for those aged 40 to 42, around 10 per cent using their own eggs.
This is why the growth areas in UK fertility care are now pre-conception screening and elective egg freezing – HFEA data shows egg storage cycles rose from 4,700 in 2022 to 6,900 in 2023, one of the fastest-growing treatments in the sector.
A focused fertility consultation earlier in the timeline – in the late twenties or very early thirties, before there is a known problem – tends to produce better decisions than a consultation triggered by a year of trying without success.
The wider picture
The UK’s falling fertility rate is the product of a society that has reorganised when people have children, not one in which couples have become less capable of conceiving.
There is no need for alarm in that finding. The practical takeaway is that the old default of ‘wait and see’ assumes a timeline no longer matching the one most people now live.
For anyone currently trying, or planning to try soon, the single most useful move is to understand your own numbers earlier than previous generations did.
The national trend is not going to reverse quickly.
A clear picture of your own fertility window – and the information to use it well – is within reach in a way the headline statistics are not.
If you are trying to conceive or thinking about starting, a structured pre-conception review is a reasonable first step.
Disclaimer: This article is produced for informational purposes only and does not constitute medical advice, diagnosis or treatment. Clinical guidance referenced reflects published NHS, ONS and HFEA data as at April 2026. Individual circumstances vary; readers are advised to consult a qualified healthcare professional before acting on any information in this article. This piece was produced in association with Spital Clinic, which provided background clinical information for editorial purposes. Hyperlinks to external sources are included for reference only and do not represent an endorsement of any product, service or organisation.
News
Women’s digital health market set to reach US$5.28 billion in 2026 – report
Entrepreneur5 days agoFuture Fertility raises Series A financing to scale AI tools redefining fertility care worldwide
Entrepreneur4 weeks agoThree sessions that show exactly where women’s health is heading in 2026
Pregnancy4 weeks agoHow NIPT has evolved and what AI NIPT means in 2026
News4 weeks agoTwo weeks left to make your mark in women’s cardiovascular health
Opinion4 weeks agoQ1 momentum: Female founders are advancing, but the system still hasn’t caught up
Fertility2 weeks agoFuture Fertility partners with Japan’s leading IVF provider, Kato Ladies Clinic
Mental health1 week agoLifting weights shows mental health and cognitive benefits in older women, study finds
Menopause2 weeks agoMore research needed to understand link between brain fog and menopause, expert says















